Published in Nature on January 22, 2009
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem (2010) 8.09
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature (2009) 5.24
The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev (2009) 3.30
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
MicroRNAs and cardiac pathology. Nat Rev Cardiol (2009) 2.50
Therapeutic genome editing: prospects and challenges. Nat Med (2015) 2.42
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 2.15
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther (2009) 2.09
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol (2009) 1.77
Principles of early drug discovery. Br J Pharmacol (2011) 1.68
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res (2012) 1.60
Diabetes complications: the microRNA perspective. Diabetes (2011) 1.60
Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat Biotechnol (2014) 1.52
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A (2012) 1.52
Retracted Selective cell death mediated by small conditional RNAs. Proc Natl Acad Sci U S A (2010) 1.51
Mammalian cell transfection: the present and the future. Anal Bioanal Chem (2010) 1.51
Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater (2010) 1.50
Developing therapeutic microRNAs for cancer. Gene Ther (2011) 1.49
Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes. Nano Lett (2011) 1.49
Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci (2014) 1.49
Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front Physiol (2012) 1.49
PAK1 as a therapeutic target. Expert Opin Ther Targets (2010) 1.48
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest (2011) 1.46
Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med (2016) 1.40
Novel functions for small RNA molecules. Curr Opin Mol Ther (2009) 1.39
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res (2011) 1.35
Lipidic systems for in vivo siRNA delivery. AAPS J (2009) 1.33
Genome-based analysis of the nonhuman primate Macaca fascicularis as a model for drug safety assessment. Genome Res (2011) 1.33
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids (2014) 1.32
Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem (2011) 1.32
RNA viruses and the host microRNA machinery. Nat Rev Microbiol (2013) 1.31
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A (2014) 1.30
Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther (2010) 1.28
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine (2012) 1.27
Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA (2011) 1.26
RNAstructure: Web servers for RNA secondary structure prediction and analysis. Nucleic Acids Res (2013) 1.25
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small (2010) 1.23
Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface (2009) 1.22
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 1.21
Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res (2009) 1.21
Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal (2013) 1.20
siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics (2009) 1.20
Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res (2013) 1.20
Novel RNA-based strategies for therapeutic gene silencing. Mol Ther (2010) 1.20
Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury. Am J Respir Cell Mol Biol (2010) 1.19
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res (2012) 1.16
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
MicroRNAs: small RNAs with big effects. Transplantation (2010) 1.15
Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery. Theranostics (2013) 1.14
Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther (2010) 1.14
Effective gene silencing by multilayered siRNA-coated gold nanoparticles. Small (2010) 1.13
The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides (2010) 1.13
New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol (2012) 1.11
Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res (2009) 1.11
RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet (2011) 1.10
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One (2014) 1.09
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07
Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers. Mol Pharm (2012) 1.06
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol (2015) 1.05
Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05
Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res (2010) 1.05
Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med (2009) 1.04
Clinical status of duplex RNA. Bioorg Med Chem Lett (2010) 1.04
Translating materials design to the clinic. Nat Mater (2013) 1.03
Quantitative evaluation of siRNA delivery in vivo. RNA (2010) 1.03
HBV life cycle and novel drug targets. Hepatol Int (2011) 1.03
Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res (2011) 1.02
Rational design of immunostimulatory siRNAs. Mol Ther (2010) 1.02
Molecular diagnostics in transplantation. Nat Rev Nephrol (2010) 1.01
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol (2010) 1.00
Regulation of miRNA biogenesis and turnover in the immune system. Immunol Rev (2013) 1.00
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. Mol Pharm (2011) 0.99
Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol (2011) 0.99
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release (2012) 0.99
Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol (2010) 0.98
Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells. Proc Natl Acad Sci U S A (2012) 0.98
Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.97
Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol (2011) 0.97
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods (2011) 0.97
Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale (2012) 0.96
Next steps in cardiovascular disease genomic research--sequencing, epigenetics, and transcriptomics. Clin Chem (2011) 0.95
Dendronized gold nanoparticles for siRNA delivery. Small (2012) 0.95
Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses. PLoS Negl Trop Dis (2012) 0.95
Computational prediction of the localization of microRNAs within their pre-miRNA. Nucleic Acids Res (2013) 0.94
Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94
Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin Biol Ther (2009) 0.94
Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs. ACS Chem Biol (2010) 0.94
Multi-task learning for cross-platform siRNA efficacy prediction: an in-silico study. BMC Bioinformatics (2010) 0.94
Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol Ther (2013) 0.93
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
The impact of microRNAs on protein output. Nature (2008) 32.39
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 20.32
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Control of stress-dependent cardiac growth and gene expression by a microRNA. Science (2007) 12.08
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature (2008) 10.71
Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. Nature (2008) 10.11
The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science (2007) 9.36
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell (2005) 9.35
RNAi-mediated targeting of heterochromatin by the RITS complex. Science (2004) 8.73
Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells. Science (2008) 8.62
An endogenous small interfering RNA pathway in Drosophila. Nature (2008) 7.88
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 7.29
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
RNAi-mediated pathways in the nucleus. Nat Rev Genet (2005) 6.55
Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell (2005) 6.47
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol (2005) 5.60
Drosophila endogenous small RNAs bind to Argonaute 2 in somatic cells. Nature (2008) 5.59
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
RNA interference in adult mice. Nature (2002) 5.33
RNA-directed de novo methylation of genomic sequences in plants. Cell (1994) 5.26
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
The Drosophila hairpin RNA pathway generates endogenous short interfering RNAs. Nature (2008) 5.05
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A (2004) 4.85
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
PRG-1 and 21U-RNAs interact to form the piRNA complex required for fertility in C. elegans. Mol Cell (2008) 4.48
Biogenesis and germline functions of piRNAs. Development (2007) 4.37
Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol (2008) 4.29
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
Slicer and the argonautes. Nat Chem Biol (2007) 3.99
Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med (2008) 3.83
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Inhibition of respiratory viruses by nasally administered siRNA. Nat Med (2004) 3.69
Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol (2004) 3.67
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
Piwi and piRNAs act upstream of an endogenous siRNA pathway to suppress Tc3 transposon mobility in the Caenorhabditis elegans germline. Mol Cell (2008) 3.37
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2005) 3.28
Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature (2008) 3.07
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med (2005) 2.80
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med (2005) 2.80
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther (2006) 2.59
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med (2005) 2.55
The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol (2008) 2.51
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol (2008) 1.96
siRNA relieves chronic neuropathic pain. Nucleic Acids Res (2004) 1.96
The role of the RNAi machinery in heterochromatin formation. Cell (2005) 1.89
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther (2006) 1.86
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev (2007) 1.48
shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev (2007) 1.42
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett (2004) 1.41
Therapeutic potential for microRNAs. Adv Drug Deliv Rev (2007) 1.41
Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res (2008) 1.37
Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol (2004) 1.22
Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res (2006) 1.14
Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res (2007) 1.06
Predicting siRNA efficiency. Cell Mol Life Sci (2007) 1.05
Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J Immunol (2008) 1.04
RNA interference: big applause for silencing in Stockholm. Cell (2006) 1.03
2'-fluoro-4'-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res (2007) 1.03
RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv (2007) 1.00
Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol Ther (2008) 0.99
Attenuation of alpha2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood. Neuroscience (2004) 0.95
Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci (2008) 0.87
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (2005) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Functional siRNA expression from transfected PCR products. RNA (2002) 1.42
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A (2009) 1.38
HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res (2005) 1.37
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR. Nucleic Acids Res (2009) 1.35
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther (2007) 1.34
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther (2003) 1.29
RNAi and the P-body connection. Nat Cell Biol (2005) 1.29
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res (2008) 1.25
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19
A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Expressing short hairpin RNAs in vivo. Nat Methods (2006) 1.14
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res (2010) 1.11
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther (2003) 1.10
Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther (2007) 1.08
Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07
Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07
Control of HIV-1 replication by RNA interference. Virus Res (2004) 1.05
Amplification of RNAi--targeting HLA mRNAs. Mol Ther (2005) 1.05
Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev (2003) 1.04
Uncoupling of RNAi from active translation in mammalian cells. RNA (2004) 1.04
Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One (2012) 1.04
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol (2005) 1.03
Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02
The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem (2009) 0.99
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B). J Mol Cell Cardiol (2004) 0.98
Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. Anal Chem (2012) 0.98
Epigenetics and microRNAs. Pediatr Res (2007) 0.98
Progress in RNAi-based antiviral therapeutics. Methods Mol Biol (2011) 0.98
Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum Gene Ther (2006) 0.98
Sensing the danger in RNA. Nat Med (2005) 0.97
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods (2011) 0.97
Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol (2011) 0.94
Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. Mol Ther (2004) 0.93
Principles of Dicer substrate (D-siRNA) design and function. Methods Mol Biol (2008) 0.93
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
Recent applications of RNAi in mammalian systems. Curr Pharm Biotechnol (2004) 0.92
Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. Methods Enzymol (2005) 0.91
Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses (2013) 0.91
Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. Mol Ther (2008) 0.91
MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol Sci (2011) 0.90